Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan;17(1):57-63.
doi: 10.1007/s10048-015-0461-1. Epub 2015 Oct 13.

Transgenic rescue of phenotypic deficits in a mouse model of alternating hemiplegia of childhood

Affiliations

Transgenic rescue of phenotypic deficits in a mouse model of alternating hemiplegia of childhood

Greer S Kirshenbaum et al. Neurogenetics. 2016 Jan.

Abstract

Missense mutations in ATP1A3 encoding Na(+),K(+)-ATPase α3 are the primary cause of alternating hemiplegia of childhood (AHC). Most ATP1A3 mutations in AHC lie within a cluster in or near transmembrane α-helix TM6, including I810N that is also found in the Myshkin mouse model of AHC. These mutations all substantially reduce Na(+),K(+)-ATPase α3 activity. Herein, we show that Myshkin mice carrying a wild-type Atp1a3 transgene that confers a 16 % increase in brain-specific total Na(+),K(+)-ATPase activity show significant phenotypic improvements compared with non-transgenic Myshkin mice. Interventions to increase the activity of wild-type Na(+),K(+)-ATPase α3 in AHC patients should be investigated further.

Keywords: Alternating hemiplegia; Atp1a3; Mice; Na+,K+-ATPase α3; Transgenic rescue.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Body weight (% of +/+; mean ± SEM) of male (n = 6/genotype) and female (n = 6/genotype) Myk/+, Myk/+/Tg, and Tg/+ mice at 4 and 8 weeks of age. For body weight at 4 weeks, main effects of Atp1a3 genotype (F(1, 42) = 8.41, p < 0.01), sex (F(1, 42) = 7.40, p < 0.01), and Atp1a3 genotype by Tg genotype interaction (F(1, 42) = 12.69, p < 0.001) were observed. For body weight at 8 weeks, main effects of Atp1a3 genotype (F(1, 42) = 14.18, p < 0.001), Tg genotype (F(1, 42) = 8.84, p < 0.01), sex (F(1, 42) = 82.72, p < 0.0001), and Atp1a3 genotype by Tg genotype interaction (F(1, 42) = 10.83, p < 0.01) were observed. *p < 0.05; **p < 0.01; ***p < 0.001 compared with +/+ mice
Fig. 2
Fig. 2
Balance beam performance of +/+, Myk/+, Myk/+/Tg, and Tg/+ mice (n = 12/genotype). a Number of hind foot slips (mean ± SEM) and b traversal time (s; mean ± SEM) when traversing a narrow beam. For the number of foot slips, main effects of Atp1a3 genotype (F(1, 42) = 14.11, p < 0.001) and Atp1a3 genotype by Tg genotype interaction (F(1, 42) = 5.02, p < 0.05) were observed. For traversal time, main effects of Atp1a3 genotype (F(1, 42) = 22.19, p < 0.0001), Tg genotype (F(1, 42) = 5.52, p < 0.05), and Atp1a3 genotype by Tg genotype interaction (F(1, 42) = 9.54, p < 0.01) were observed. ***p < 0.001; ****p < 0.0001 compared with +/+ mice
Fig. 3
Fig. 3
Water maze and fear-conditioning performance of +/+, Myk/+, Myk/+/Tg, and Tg/+ mice (n = 12/genotype). a Escape latency (s; mean ± SEM). Main effects of Atp1a3 genotype (F(1, 42) = 77.09, p < 0.0001) and Tg genotype (F(1, 42) = 7.79, p < 0.01) were observed for latency. b Swim path length (m; mean ± SEM). Main effects of Atp1a3 genotype (F(1, 42) = 67.20, p < 0.0001) and Tg genotype (F(1, 42) = 9.10, p < 0.01) were observed for path length. c Thigmotaxis (% time; mean ± SEM). Main effects of Atp1a3 genotype (F(1, 42) = 53.10, p < 0.0001) and Tg genotype (F(1, 42) = 4.59, p < 0.05) were observed for thigmotaxis. d Freezing levels (% time; mean ± SEM) of mice when test-naïve (baseline) and when returned to the chamber 24 h after training (context). For baseline freezing, a main effect of Tg genotype (F(1, 42) = 11.60, p < 0.01) was observed. For context freezing, main effects of Atp1a3 genotype (F(1, 42) = 5.33, p < 0.05), Tg genotype (F(1, 42) = 7.40, p < 0.01), and Atp1a3 genotype by Tg genotype interaction (F(1, 42) = 10.01, p < 0.01) were observed. **p < 0.01; ***p < 0.001; ****p < 0.0001 compared with +/+ mice. †p < 0.05 compared with Myk/+ mice. ##p < 0.01; ####p < 0.0001 compared with baseline freezing for each genotype. n.s. not significant

References

    1. Sweney MT, Silver K, Gerard-Blanluet M, Pedespan JM, Renault F, Arzimanoglou A, Schlesinger-Massart M, Lewelt AJ, Reyna SP, Swoboda KJ. Alternating hemiplegia of childhood: early characteristics and evolution of a neurodevelopmental syndrome. Pediatrics. 2009;123:e534–41. doi: 10.1542/peds.2008-2027. - DOI - PubMed
    1. Panagiotakaki E, Gobbi G, Neville B, Ebinger F, Campistol J, Nevsímalová S, Laan L, Casaer P, Spiel G, Giannotta M, Fons C, Ninan M, Sange G, Schyns T, Vavassori R, Poncelin D, ENRAH Consortium. Arzimanoglou A. Evidence of a non-progressive course of alternating hemiplegia of childhood: study of a large cohort of children and adults. Brain. 2010;133:3598–610. doi: 10.1093/brain/awq295. - DOI - PubMed
    1. Heinzen EL, Arzimanoglou A, Brashear A, Clapcote SJ, Gurrieri F, Goldstein DB, Jóhannesson SH, Mikati MA, Neville B, Nicole S, Ozelius LJ, Poulsen H, Schyns T, Sweadner KJ, van den Maagdenberg A, Vilsen B, ATP1A3 Working Group Distinct neurological disorders with ATP1A3 mutations. Lancet Neurol. 2014;13:503–14. doi: 10.1016/S1474-4422(14)70011-0. - DOI - PMC - PubMed
    1. Benarroch EE. Na+, K+-ATPase: functions in the nervous system and involvement in neurologic disease. Neurology. 2011;76:287–93. doi: 10.1212/WNL.0b013e3182074c2f. - DOI - PubMed
    1. Rosewich H, Ohlenbusch A, Huppke P, Schlotawa L, Baethmann M, Carrilho I, Fiori S, Lourenço CM, Sawyer S, Steinfeld R, Gärtner J, Brockmann K. The expanding clinical and genetic spectrum of ATP1A3-related disorders. Neurology. 2014;82:945–55. doi: 10.1212/WNL.0000000000000212. - DOI - PubMed

Publication types

Substances

Supplementary concepts